Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study

BMJ (Online)

Volumn 344, Issue 7840, 2012, Pages

  Rosario, Derek J ^a   Lane, J Athene ^b   Metcalfe, Chris ^b   Donovan, Jenny L ^b   Doble, Andy ^c   Goodwin, Louise ^a   Davis, Michael ^a   Catto, James W F ^a   Avery, Kerry ^b   Neal, David E ^d   Hamdy, Freddie C ^e  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLEEDING; COHORT ANALYSIS; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEVER; HEALTH CARE UTILIZATION; HEMATOCHEZIA; HEMATURIA; HEMOEJACULATE; HUMAN; INFECTION COMPLICATION; MALE; OUTCOME ASSESSMENT; PAIN; PATIENT ATTITUDE; PATIENT COUNSELING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; REPEAT PROCEDURE; TRANSRECTAL ULTRASONOGRAPHY; ATTITUDE TO HEALTH; BIOPSY; BLOOD; CLINICAL TRIAL; ENDOSCOPIC ECHOGRAPHY; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; POSTOPERATIVE COMPLICATION; PROSTATE; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; TIME;

AGED; ATTITUDE TO HEALTH; BIOPSY; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84857153683     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d7894     Document Type: Article

References (42)

1. Ferlay J, Shin HR, Bray F, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase no 10. International Agency for Research on Cancer, 2010.
2. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
3. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-32.
4. Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010;341:c4543.
5. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1974;142:71-4.
6. Patel AR, Jones JS. Optimal biopsy strategies for the diagnosis and staging of prostate cancer. Curr Opin Urol 2009;19:232-7.
7. Loeb S. Prostate biopsy: a risk-benefit analysis. J Urol 2010;183:852-3.
8. Lee G, Attar K, Laniado M, Karim O. Trans-rectal ultrasound guided biopsy of the prostate: nationwide diversity in practice and training in the United Kingdom. Int Urol Nephrol 2007;39:185-8. (Pubitemid 46722964)
9. Leippold T, Preusser S, Engeler D, Inhelder F, Schmid HP. Prostate biopsy in Switzerland: a representative survey on how Swiss urologists do it. Scand J Urol Nephrol 2008;42:18-23.
10. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schroder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002;60:826-30. (Pubitemid 35300348)
11. Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 2001;166:856-60. (Pubitemid 32750966)
12. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006;175:1605-12.
13. Irani J, Fournier F, Bon D, Gremmo E, Dore B, Aubert J. Patient tolerance of transrectal ultrasound-guided biopsy of the prostate. Br J Urol 1997;79:608-10. (Pubitemid 28321106)
14. Mkinen T, Auvinen A, Hakama M, Stenman UH, Tammela TL. Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. Urology 2002;60:846-50. (Pubitemid 35300352)
15. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer 2010;46:3095-101.
16. Donovan JL, Mills N, Smith M, Brindle L, Jacoby A, Peters T, et al. Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. BMJ 2002;325:766-70.
17. Donovan JL, Peters TJ, Abrams P, Brookes ST, de la Rosette JJ, Schafer W. Scoring the short form ICSmaleSF questionnaire. J Urol 2000;164:1948-55.
18. Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 2004;23:322-30. (Pubitemid 38859423)
19. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 1998;36:1002-12. (Pubitemid 128456439)
20. Rosario DJ, Lane JA, Metcalfe C, Catto JW, Dedman D, Donovan JL, et al. Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study. Eur Urol 2008;53:777-84.
21. Eskicorapci SY, Baydar DE, Akbal C, Sofikerim M, Gunay M, Ekici S, et al. An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer. Eur Urol 2004;45:444-8. (Pubitemid 38376201)
22. Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol 2004;22:19-22. (Pubitemid 41095109)
23. Welch HG, Fisher ES, Gottlieb DJ, Barry MJ. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst 2007;99:1395-400. (Pubitemid 351767186)
24. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994;151:1571-4. (Pubitemid 24151304)
25. Hambrock T, Somford DM, Hoeks C, Bouwense SA, Huisman H, Yakar D, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010;183:520-7.
26. Braun KP, Brookman-Amissah S, May M, Grassmel Y, Heintze C, Hoschke B, et al. The significance of rebiopsy in the diagnosis of prostate cancer. Urologe A 2009;48:163-9.
27. Herranz AF, Rodriguez FE, Cordero JM, Lledo GE, Verdu TF, Gonzalez CF, et al. [Morbidity of and tolerance to ultrasonography-guided transrectal biopsy of the prostate.] [Spanish.] Acta Urol Esp 1996;20:858-66.
28. Tiong HY, Liew LC, Samuel M, Consigliere D, Esuvaranathan K. A meta-analysis of local anesthesia for transrectal ultrasound-guided biopsy of the prostate. Prostate Cancer Prostatic Dis 2007;10:127-36. (Pubitemid 46881663)
29. Hergan L, Kashefi C, Parsons JK. Local anesthetic reduces pain associated with transrectal ultrasound-guided prostate biopsy: a meta-analysis. Urology 2007;69:520-5. (Pubitemid 46428396)
30. Ingber MS, Ibrahim I, Turzewski C, Hollander JB, Diokno AC. Does periprostatic block reduce pain during transrectal prostate biopsy? A randomized, placebo-controlled, double-blinded study. Int Urol Nephrol 2010;42:23-7.
31. Wolf JS Jr, Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008;179:1379-90.
32. Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000;85:682-5. (Pubitemid 30192834)
33. Kapoor DA, Klimberg IW, Malek GH, Wegenke JD, Cox CE, Patterson AL, et al. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 1998;52:552-8. (Pubitemid 28440157)
34. Schaeffer AJ, Montorsi F, Scattoni V, Perroncel R, Song J, Haverstock DC, et al. Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate. BJU Int 2007;100:51-7. (Pubitemid 46878540)
35. Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010;183:963-8.
36. Sexton WJ. Editorial comment. J Urol 2010;183:969.
37. Cannon GM Jr, Smaldone MC, Paterson DL. Extended-spectrum beta-lactamase gram-negative sepsis following prostate biopsy: implications for use of fluoroquinolone prophylaxis. Can J Urol 2007;14:3653-5.
38. Carlson WH, Bell DG, Lawen JG, Rendon RA. Multi-drug resistant E coli urosepsis in physicians following transrectal ultrasound guided prostate biopsies - three cases including one death. Can J Urol 2010;17:5135-7.
39. Chappell B, O'Brien T. Infections after prostate biopsy and antibiotic resistance. BJU Int 2009;103:409.
40. Thompson PM, Philpott-Howard J, Wang W. Is the current antibiotic prophylaxis policy in transrectal prostate biopsy still safe? BJU Int 2009;104:271-2.
41. Burden HP, Ranasinghe W, Persad R. Antibiotics for transrectal ultrasonography-guided prostate biopsy: are we practising evidence-based medicine? BJU Int 2008;101:1202-4. (Pubitemid 351549638)
42. Gallina A, Suardi N, Montorsi F, Capitanio U, Jeldres C, Saad F, et al. Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men. Int J Cancer 2008;123:647-52. (Pubitemid 351898424)